This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Published Erratum

. 2021 Feb;9(2):1.

doi: 10.1136/jitc-2020-001622corr1.

Correction : Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

No authors listed

PMID: 33579740
PMCID: PMC7883864
DOI: 10.1136/jitc-2020-001622corr1

Published Erratum

Correction : Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer

No authors listed. J Immunother Cancer. 2021 Feb.

. 2021 Feb;9(2):1.

doi: 10.1136/jitc-2020-001622corr1.

PMID: 33579740
PMCID: PMC7883864
DOI: 10.1136/jitc-2020-001622corr1

No abstract available

PubMed Disclaimer

Erratum for

Safety of immune checkpoint inhibitor rechallenge after discontinuation for grade ≥2 immune-related adverse events in patients with cancer.
Allouchery M, Lombard T, Martin M, Rouby F, Sassier M, Bertin C, Atzenhoffer M, Miremont-Salame G, Perault-Pochat MC, Puyade M; French Network of Regional Pharmacovigilance Centers. Allouchery M, et al. J Immunother Cancer. 2020 Dec;8(2):e001622. doi: 10.1136/jitc-2020-001622. J Immunother Cancer. 2020. PMID: 33428586 Free PMC article.

Publication types

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations